U.S. Markets open in 4 hrs 53 mins
  • S&P Futures

    3,256.00
    -46.25 (-1.40%)
     
  • Dow Futures

    26,175.00
    -382.00 (-1.44%)
     
  • Nasdaq Futures

    11,132.75
    -210.00 (-1.85%)
     
  • Russell 2000 Futures

    1,542.30
    -16.10 (-1.03%)
     
  • Crude Oil

    36.20
    +0.03 (+0.08%)
     
  • Gold

    1,872.40
    +4.40 (+0.24%)
     
  • Silver

    23.39
    +0.02 (+0.11%)
     
  • EUR/USD

    1.1677
    -0.0001 (-0.0117%)
     
  • 10-Yr Bond

    0.8350
    0.0000 (0.00%)
     
  • Vix

    39.51
    -0.77 (-1.91%)
     
  • GBP/USD

    1.2925
    +0.0002 (+0.0142%)
     
  • USD/JPY

    104.2750
    -0.3350 (-0.3202%)
     
  • BTC-USD

    13,277.82
    -96.36 (-0.72%)
     
  • CMC Crypto 200

    260.38
    +17.71 (+7.30%)
     
  • FTSE 100

    5,564.01
    -17.74 (-0.32%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit

Apellis Pharmaceuticals, Inc.
·1 min read

WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at Stifel’s 2020 Immunology and Inflammation Virtual Summit on Thursday, October 1, 2020 at 9:00 a.m. ET.

Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a panel discussion titled “The Evolution of Complement Targeted Therapies.” The event will be available live via webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. For more information, please visit http://apellis.com.

Investor Contact:
Sam Martin / Maghan Meyers
Argot Partners
sam@argotpartners.com / maghan@argotpartners.com
212.600.1902